Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04357834
Other study ID # WAVE
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 22, 2020
Est. completion date June 30, 2021

Study information

Verified date August 2021
Source University Hospital Inselspital, Berne
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim is to develop a wearable-based ICU (intensive care unit) prediction algorithm for inpatients contracted with SARS-CoV-2. Inpatients with suspicion of COVID-19 or with confirmed SARS-CoV-2 infection will be included. The participants will be equipped with a smartwatch, which gathers physiological data throughout hospitalisation.


Description:

The SARS-CoV-2 pandemic puts an unprecedented burden on the healthcare system, specifically its healthcare providers and the resource demands for intensive care units (ICUs). To support effective care despite large case numbers, hospital operations urgently need improved decision support in early identification of patients at risk of an acute COVID-19 deterioration that requires ICU. The investigators aim at developing a wearable-based ICU algorithm for inpatients contracted with SARS-CoV-2. Inpatients on the general ward with suspicion of COVID-19 or with confirmed SARS-CoV-2 infection will be included. The participant will be equipped with a smartwatch and wear the device throughout the hospital stay until the patient (1) is discharged home, (2) is transferred to the ICU, or (3) palliative care is initiated. The smartwatch collects several physiological parameters (e.g. heart rate, heart rate variability, respiration rate, oxygen saturation). The collected data will be used to develop an ICU prediction algorithm to detect patients at risk of an acute COVID-19 deterioration that requires ICU.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date June 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility Inclusion Criteria: - Informed consent as documented by signature - Age >= 18 years - Suspicion of COVID-19 or patient tested positive for SARS-CoV-2 - Hospitalisation on the general ward Exclusion Criteria: - Smartwatch cannot be attached around the wrist of the patient - Direct transfer from the emergency department or external institution to ICU (i.e. no hospitalization on the general ward) - Known allergies to components of the smartwatch - Rejection of ICU transfer in the patient decree

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Equipment with smartwatch throughout hospital stay on the general ward
Participants with confirmed SARS-CoV-2 infection or suspicion of COVID-19 will be equipped with a smartwatch and wear the device throughout the hospital stay on the general ward.

Locations

Country Name City State
Switzerland Emergency Department, University Hospital Bern, Inselspital Bern

Sponsors (2)

Lead Sponsor Collaborator
University Hospital Inselspital, Berne ETH Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic accuracy of smartwatch data in predicting ICU requirement in COVID-19 contracted inpatients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85). Accuracy of the WAVE-model will be assessed using physiological data recorded by the smartwatch (Garmin vivoactive 4) during hospitalization complemented by demographic and health-related patient-information and will be analysed using applied machine learning technology for ICU prediction. until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Diagnostic accuracy of routine physiological data in predicting ICU requirement in COVID-19 contracted in-patients quantified as the area under the receiver operator characteristics curve (AUC ROC > 0.85). Accuracy of the model will be assessed using physiological data routinely recorded during hospitalization and will be analysed using applied machine learning technology for ICU prediction. until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Diagnostic accuracy of predicting hospital discharge without ICU admission in COVID-19 contracted in-patients quantified as area under the receiver operator characteristics curve Accuracy of the model will be assessed using data on comorbidities, medication treatment during hospitalization and physiological data and will be analysed using casual machine-learning approaches until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of heart rate from baseline (hospitalization) to ICU admission Heart rate will be recorded throughout the hospitalization using a smartwatch (Garmin vivoactive 4S) and using routine medical monitors. until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of heart rate variability from baseline (hospitalization) to ICU admission Heart rate variability will be recorded throughout the hospitalization using a smartwatch (Garmin vivoactive 4S) until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of skin temperature from baseline (hospitalization) to ICU admission Skin temperature will be recorded throughout the hospitalization using a smartwatch (Garmin vivoactive 4S) until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of blood oxygen saturation from baseline (hospitalization) to ICU admission Blood oxygen saturation will be recorded throughout the hospitalization using a smartwatch (Garmin vivoactive 4S) and using routine medical monitors until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of respiration rate from baseline (hospitalization) to ICU admission Respiration rate will be recorded throughout the hospitalization using a smartwatch (Garmin vivoactive 4S) and using routine medical monitors until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of physical activity from baseline (hospitalization) to ICU admission Physical activity will be recorded throughout the hospitalization using a smartwatch (Garmin vivoactive 4S) until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of stress level from baseline (hospitalization) to ICU admission Stress level will be recorded throughout the hospitalization using a smartwatch (Garmin vivoactive 4S) until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of sleep pattern from baseline (hospitalization) to ICU admission Sleep will be recorded throughout the hospitalization using a smartwatch (Garmin vivoactive 4S) until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of steps per day from baseline (hospitalization) to ICU admission Steps per day will be recorded throughout the hospitalization using a smartwatch (Garmin vivoactive 4S) until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of systolic blood pressure from baseline (hospitalization) to ICU admission Systolic blood pressure will be recorded throughout the hospitalization using a smartwatch (Garmin vivoactive 4S) and using routine medical monitors until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of diastolic blood pressure from baseline (hospitalization) to ICU admission Diastolic blood pressure will be recorded throughout the hospitalization using a smartwatch (Garmin vivoactive 4S) and using routine medical monitors until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of body temperature from baseline (hospitalization) to ICU admission Body temperature will be recorded throughout the hospitalization using a routine medical thermometer until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of oxygen partial pressure (pO2) from baseline (hospitalization) to ICU admission Oxygen partial pressure (pO2) will be routinely assessed during the hospitalization in arterial or venous blood gas analyses until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of CO2 partial pressure (pCO2) from baseline (hospitalization) to ICU admission CO2 partial pressure (pCO2) will be routinely assessed during the hospitalization in arterial or venous blood gas analyses until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of blood pH from baseline (hospitalization) to ICU admission Blood pH will be routinely assessed during the hospitalization in arterial or venous blood gas analyses until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of bicarbonate from baseline (hospitalization) to ICU admission Bicarbonate will be routinely assessed during the hospitalization in arterial or venous blood gas analyses until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of base excess from baseline (hospitalization) to ICU admission Base excess will be routinely assessed during the hospitalization in arterial or venous blood gas analyses until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
Secondary Change of oxygen flow rate from baseline (hospitalization) to ICU admission Oxygen flow rate will be routinely assessed during the hospitalization until hospital discharge, transfer to ICU or palliative care is initiated (expected to be on average after 7-30 days)
See also
  Status Clinical Trial Phase
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Active, not recruiting NCT04420676 - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Completed NCT04425720 - Use of Remote Monitoring for COVID-19 Patient N/A
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04419610 - RAS and Coagulopathy in COVID19 Early Phase 1
Completed NCT04546581 - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Phase 3
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Not yet recruiting NCT04524156 - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2 N/A
Completed NCT04441710 - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Terminated NCT04614025 - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 Phase 2
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2
Recruiting NCT04397705 - Remote Monitoring of Cancer Patients With Suspected Covid-19 Phase 1